Why trust GLP Chart.
What we measure, who measures it, what we won't take money for, and how we handle being wrong.
Scoring and the team
Every program is scored on five pillars (pricing, cancellation, onboarding, medication options, member feedback) on the same 0 to 10 rubric. The full dimension definitions, data sources, and verification steps are on the methodology page. The rubric has not changed since April 1, 2026.
John Samaras, editor, is the single decision-maker on program inclusion and scoring. He works on this full time from Austin, Texas. LinkedIn · Full bio
Every clinical claim is sourced to a published registration trial or the approved prescribing information. Clinical content is not clinician-authored medical advice.
Paid placements: zero
Rank order is locked before any commercial relationship exists. Where a Visit link is an affiliate link, it is marked sponsored per FTC and Google rules. See the full GLP Chart Pledge for the seven editorial commitments.
Revenue model
We earn affiliate commissions on some visit links. The commission does not affect scoring or rank order. No program pays to be listed. Some visit links earn us a commission. We do not sell placement, sponsored content, or email-list rentals. Full breakdown on the About page.
Independence policy
GLP Chart is owned and operated by John Samaras, an independent editorial operator based in Austin, Texas. There are no outside investors or venture capital behind it, no preferred partnerships with any program in the chart, and no equity in any of the companies reviewed. We do not let any program in the chart approve or preview our content before publication. We do not accept gifts, free samples, sponsored trips, consulting fees, or speaking honoraria from any program in the chart or any GLP-1 pharmaceutical manufacturer.
Programs we decline to cover
We do not list programs that:
- Refuse to publish their pricing publicly
- Refuse to disclose their compounding pharmacy partner
- Make claims about unapproved peptides (AOD-9604, BPC-157, MOTS-c, etc.)
- Use deceptive comparison advertising against named competitors
- Have outstanding state pharmacy-board sanctions or FDA warning letters
- Operate without a state-licensed prescribing clinician for the patient's state of residence
This is a non-trivial list of programs and we lose affiliate revenue by declining them. We do it anyway because the chart's value depends on excluding programs we wouldn't personally recommend to family.
Disclosed conflicts and prior affiliations
John currently has no employment relationship with any program in the chart and no consulting role with any pharmaceutical manufacturer. He holds no investment position, public or private, in any company covered. If circumstances change (consulting work, investment, employment), the change will be disclosed here within 30 days and any affected coverage will be reviewed.
What programs publish
Every monthly maintenance price on the chart was confirmed in the last 30 days against the program's published pricing pages, not a marketing claim or an advertised teaser. We read the maintenance-dose figure the program publishes, and when a program's site blocks automated access we confirm it through a web search of the program's own materials. We cite the published source for every price. When a price moves, the change appears in the What moved this week callout in the newsroom and gets a row in the corrections log.
Corrections log
When we get something wrong, we say so publicly with a date. We do not silently edit a published score or claim. The full corrections log is published with each Monday price check. Recent corrections:
Found a problem?
Email corrections@glpchart.com. We respond within one business day. If a published claim is wrong, the correction goes up in the next Monday price check with your name credited (with permission).
We email you when a price moves.
We check every program against published pricing every Monday. When a price moves or a lock-in clause appears, you hear about it first.
